netFormulary
 Report : Medicines with links to NICE 22/07/2019 04:29:17

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Non Formulary Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) (TA280)
Abiraterone 08.03.04.02 Non Formulary Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy) (TA259)
Adalimumab 13.05.03 Non Formulary Psoriasis - adalimumab (TA146)
Adalimumab 10.01.03 Non Formulary Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)
Adalimumab 10.01.03 Non Formulary Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130)
Adalimumab 10.01.03 Non Formulary Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143)
Adalimumab 10.01.03 Non Formulary Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)
Adalimumab 01.05.03 Non Formulary Crohn’s disease - infliximab (review) and adalimumab (review of TA40) (TA187)
Adefovir Dipivoxil 05.03.03 Non Formulary Hepatitis B (chronic) (CG165)
Adefovir Dipivoxil 05.03.03 Non Formulary Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a (TA96) (partially updated by CG165)
Afatinib 08.01.05 Non Formulary Lung cancer (non small cell, EGFR mutation positive) - afatinib (TA310)
Aflibercept 08.01 Non Formulary Colorectal cancer (metastatic) - aflibercept (TA307)
Aflibercept 11.08.02 Non Formulary Macular degeneration (wet age-related) - aflibercept (1st line) (TA294)
Aflibercept 11.08.02 Non Formulary Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)
Alitretinoin 13.05.01 Non Formulary Eczema (chronic) - alitretinoin (TA177)
Alteplase 02.10.02 Non Formulary Stroke (acute, ischaemic) - alteplase (TA264)
Aluminimum Hydroxide 01.01.01 Non Formulary Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)
Amantadine Hydrochloride 05.03.04 Non Formulary Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158)
Amantadine Hydrochloride 05.03.04 Non Formulary Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158)
Anti-D (Rh0) Immunoglobulin 14.05.03 Non Formulary Pregnancy (rhesus negative women) - routine anti-D (review) (TA156)
Apixaban 02.08.02 Non Formulary Venous thromboembolism - apixaban (hip and knee surgery) (TA245)
Apixaban 02.08.02 Non Formulary Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)
Aripiprazole 04.02.01 Formulary Bipolar disorder (adolescents) - aripiprazole (TA292)
Aripiprazole 04.02.01 Formulary Schizophrenia - aripiprazole (TA213)
Azacitidine 08.01.03 Non Formulary Myelodysplastic syndromes - azacitidine (TA218)
Basiliximab 08.02.02 Non Formulary Renal transplantation - immunosuppressive regimens for children and adolescents (TA99)
Basiliximab 08.02.02 Non Formulary Renal transplantation - immuno-suppressive regimens (adults) (TA85)
Bee and Wasp Allergen Extracts 03.04.02 Non Formulary Venom anaphylaxis - immunotherapy pharmalgen (TA246)
Bendamustine 08.01.01 Non Formulary Leukaemia (lymphocytic) - bendamustine (TA216)
Bevacizumab 08.01.05 Non Formulary Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)
Bevacizumab 08.01.05 Non Formulary Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab (TA285)
Bevacizumab 08.01.05 Non Formulary Breast cancer - bevacizumab (in combination with a taxane) (TA214)
Bevacizumab 08.01.05 Non Formulary Colorectal cancer (metastatic) - bevacizumab (TA212)
Bevacizumab 08.01.05 Non Formulary Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)
Bivalirudin 02.08.01 Non Formulary Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
Bivalirudin 02.08.01 Non Formulary Unstable angina and NSTEMI (CG94)
Boceprevir 05.03.03 Non Formulary Hepatitis C (genotype 1) - boceprevir (TA253)
Bortezomib 08.01.05 Non Formulary Multiple myeloma - bortezomib (induction therapy) (TA311)
Bortezomib 08.01.05 Non Formulary Multiple myeloma (first line) - bortezomib and thalidomide (TA228)
Bortezomib 08.01.05 Non Formulary Multiple myeloma - bortezomib (TA129)
Bosutinib 08.01.05 Non Formulary Leukaemia (chronic myeloid) - bosutinib (TA299)
Botulinum Toxin Type A 04.07.04.02 Non Formulary Migraine (chronic) - botulinum toxin type A (TA260)
Cabazitaxel 08.01.05 Non Formulary Prostate cancer - cabazitaxel (TA255)
Canagliflozin 06.01.02.03 Non Formulary Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Capecitabine 08.01.03 Non Formulary Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)
Capecitabine 08.01.03 Non Formulary Gastric cancer (advanced) - capecitabine (TA191)
Capecitabine 08.01.03 Non Formulary Diabetes (types 1 and 2) - patient education models (TA60)
Carboplatin 08.01.05 Non Formulary Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)
Carmustine 08.01.01 Non Formulary Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121)
Carmustine 08.01.01 Non Formulary Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121)
Certolizumab Pegol 10.01.03 Non Formulary Rheumatoid arthritis - certolizumab pegol (TA186)
Cetuximab 08.01.05 Non Formulary Colorectal cancer (first line) - cetuximab (TA176)
Cetuximab 08.01.05 Non Formulary Head and neck cancer - cetuximab (TA145)
Cetuximab 08.01.05 Non Formulary Head and neck cancer (squamous cell carcinoma) - cetuximab (TA172)
Cetuximab 08.01.05 Non Formulary Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) (TA242)
Cinacalcet 09.05.01.02 Non Formulary Hyperparathyroidism - cinacalcet (TA117)
Clopidogrel 02.09 Non Formulary Acute coronary syndromes - clopidogrel (TA80)
Clopidogrel 02.09 Non Formulary Acute coronary syndromes - clopidogrel (TA80)
Clopidogrel 300mg 02.09 Non Formulary http://www.nice.org.uk/guidance/TA80
Colistimethate inhaler 05.01.07 Non Formulary Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Crizotinib 08.01.05 Non Formulary Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib (TA296)
Dabigatran 02.08.02 Non Formulary Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)
Dabigatran 02.08.02 Non Formulary Atrial fibrillation - dabigatran etexilate (TA249)
Dabigatran 02.08.02 Non Formulary Venous thromboembolism - dabigatran (TA157)
Dapagliflozin 06.01.02.03 Non Formulary Type 2 diabetes - Dapagliflozin combination therapy (TA288)
Dasatinib 08.01.05 Non Formulary Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) (TA241)
Dasatinib 08.01.05 Non Formulary Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib (TA251)
Decitabine 08.01.03 Non Formulary Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Denosumab 06.06.02 Non Formulary Bone metastases from solid tumours - denosumab (TA265)
Denosumab 06.06.02 Non Formulary Osteoporotic fractures - denosumab (TA204)
Dimethyl fumarate 08.02.04 Non Formulary Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)
Docetaxel 08.01.05 Non Formulary Prostate cancer (hormone-refractory) - docetaxel (TA101)
Docetaxel 08.01.05 Non Formulary Breast cancer (early) - docetaxel (TA109)
Dronedarone 02.03.02 Non Formulary Atrial fibrillation - dronedarone (TA197)
Eltrombopag 09.01.04 Non Formulary Thrombocytopenic purpura - eltrombopag (TA293)
Entecavir 05.03.03 Non Formulary Hepatitis B - entecavir (TA153)
Entecavir 05.03.03 Non Formulary Hepatitis B (chronic) (CG165)
Enzalutamide 08.03.04.02 Non Formulary Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316)
Eplerenone 02.02.03 Non Formulary Chronic heart failure (CG108)
Eribulin 08.01.05 Non Formulary Breast cancer (advanced) - eribulin (TA250)
Erlotinib 08.01.05 Non Formulary Lung cancer (non-small-cell) - erlotinib (TA162)
Erlotinib 08.01.05 Non Formulary Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) (TA227)
Erlotinib 08.01.05 Non Formulary Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) (TA258)
Etanercept 10.01.03 Non Formulary Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)
Etanercept 10.01.03 Non Formulary Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)
Etanercept 10.01.03 Non Formulary Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143)
Etanercept 10.01.03 Non Formulary Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130)
Etanercept 10.01.03 Non Formulary Arthritis (juvenile idiopathic) - etanercept (TA35)
Etanercept 13.05.03 Non Formulary Psoriasis - efalizumab and etanercept (TA103)
Everolimus 08.01.05 Non Formulary Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)
Everolimus 08.01.05 Non Formulary Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295)
Exenatide prolonged release 06.01.02.03 Non Formulary Diabetes (type 2) - exenatide (prolonged release) (TA248)
Ezetimibe 02.12 Non Formulary Hypercholesterolaemia - ezetimibe (TA132)
Febuxostat 10.01.04 Non Formulary Hyperuricaemia - febuxostat (TA164)
Finasteride 06.04.02 Non Formulary Lower urinary tract symptoms (CG97)
Fingolimod 08.02.04 Non Formulary Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)
Fludarabine Phosphate 08.01.03 Non Formulary Leukaemia (lymphocytic) - fludarabine (TA119)
Fludarabine Phosphate 08.01.03 Non Formulary Leukaemia (lymphocytic) - fludarabine (TA29)
Fluocinolone intravitreal implant 11.04.01 Non Formulary Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301)
Fulvestrant 08.03.04.01 Non Formulary Breast cancer (metastatic) - fulvestrant (TA239)
Gefitinib 08.01.05 Non Formulary Lung cancer (non-small-cell, first line) - gefitinib (TA192)
Gemcitabine 08.01.03 Non Formulary Pancreatic cancer - gemcitabine (TA25)
Gemcitabine 08.01.03 Non Formulary Breast cancer - gemcitabine (TA116)
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121)
Golimumab 10.01.03 Formulary Psoriatic arthritis - golimumab (TA220)
Golimumab 10.01.03 Formulary Ankylosing spondylitis - golimumab (TA233)
Golimumab 10.01.03 Formulary Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab (TA225)
Idelalisib 08.01.05 Non Formulary Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)
Imatinib 08.01.05 Non Formulary Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209)
Imatinib 08.01.05 Non Formulary Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196) (TA326)
Infliximab 01.05.03 Non Formulary Ulcerative colitis (subacute manifestations) - infliximab (TA140)
Infliximab 01.05.03 Non Formulary Ulcerative colitis (acute exacerbations) - infliximab (TA163)
Infliximab 01.05.03 Non Formulary Crohn's disease - infliximab (review) and adalimumab (review of TA40) (TA187)
Infliximab 10.01.03 Formulary Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)
Infliximab 10.01.03 Formulary Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)
Infliximab 10.01.03 Formulary Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130)
Infliximab 10.01.03 Formulary Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143)
Infliximab 13.05.03 Non Formulary Psoriasis - infliximab (TA134)
Ipilimumab 08.01.05 Non Formulary Melanoma (stage III or IV) - ipilimumab (TA268)
Ipilimumab 08.01.05 Non Formulary Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Ivabradine 02.06.03 Non Formulary Chronic heart failure - ivabradine (TA267)
Lapatinib 08.01.05 Non Formulary Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) (TA257)
Lenalidomide 08.02.04 Non Formulary Multiple myeloma - lenalidomide (TA171)
Lenalidomide 08.02.04 Non Formulary Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (ta322)
Liraglutide 06.01.02.03 Non Formulary Diabetes (type 2) - liraglutide (TA203)
Lubiprostone 01.02 Non Formulary Lubiprostone for treating chronic idiopathic constipation (TA318)
Mannitol inhalation 20 Non Formulary Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Methylprednisolone 06.03.02 Non Formulary Multiple sclerosis: management of multiple sclerosis in primary and secondary care (CG186)
Mirabegron 07.04.02 Non Formulary Overactive bladder - mirabegron (TA290)
Naftidrofuryl Oxalate 02.06.04 Non Formulary Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate (TA223)
Naftidrofuryl Oxalate 02.06.04 Non Formulary Lower limb peripheral arterial disease (CG147)
Nalmefene 04.10.01 Non Formulary Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Naltrexone 04.10.03 Non Formulary Drug misuse - naltrexone (TA115)
Natalizumab 08.02.04 Non Formulary Multiple sclerosis - natalizumab (TA127)
Nilotinib 08.01.05 Non Formulary Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) (TA241)
Ocriplasmin 11.08.02 Non Formulary Vitreomacular traction - ocriplasmin (TA297)
Ofatumumab 08.02.03 Non Formulary Chronic lymphocytic leukaemia - ofatumumab (TA202)
Omalizumab 03.04.02 Non Formulary Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) (TA278)
Oseltamivir 05.03.04 Non Formulary Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158)
Oxaliplatin 08.01.05 Non Formulary Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)
Paclitaxel 08.01.05 Non Formulary Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)
Paclitaxel 08.01.05 Non Formulary Ovarian cancer - paclitaxel (review) (TA55)
Paclitaxel 08.01.05 Non Formulary Breast cancer (early) - paclitaxel (TA108)
Pazopanib 08.01.05 Non Formulary Renal cell carcinoma (first line metastatic) - pazopanib (TA215)
Peginterferon Alfa 08.02.04 Non Formulary Hepatitis C - peginterferon alfa and ribavirin (TA200)
Peginterferon Alfa 08.02.04 Non Formulary Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75)
Peginterferon Alfa 08.02.04 Non Formulary Hepatitis C - peginterferon alfa and ribavirin (TA106)
Peginterferon Alfa 08.02.04 Non Formulary Hepatitis C - peginterferon alfa and ribavirin (TA106)
Peginterferon Alfa 08.02.04 Non Formulary Hepatitis C - peginterferon alfa and ribavirin (TA200)
Peginterferon Alfa 08.02.04 Non Formulary Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75)
Pegloticase 20 Non Formulary Gout (tophaceous, severe debilitating, chronic) - pegloticase (TA291)
Pemetrexed 08.01.03 Non Formulary Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)
Pemetrexed 08.01.03 Non Formulary Lung cancer (non-small-cell, first line treatment) - pemetrexed (TA181)
Pemetrexed 08.01.03 Non Formulary Lung cancer (non small cell, non squamous) - pemetrexed (TA309)
Pemetrexed 08.01.03 Non Formulary Mesothelioma - pemetrexed disodium (TA135)
Pemetrexed 08.01.03 Non Formulary Lung cancer (non-small-cell) - pemetrexed (TA124)
Perampanel 04.08.01 Non Formulary Epilepsy (CG137)
Pimecrolimus 13.05.03 Non Formulary Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)
pirfenidone 20 Non Formulary Idiopathic pulmonary fibrosis - pirfenidone (TA282)
Pixantrone 08.01.02 Non Formulary Lymphoma (non Hodgkins, relapsed, refractory) - pixantrone monotherapy (TA306)
Prasugrel 02.09 Non Formulary Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) (TA317)
Prasugrel 02.09 Non Formulary Acute coronary syndrome - prasugrel (TA182)
Prucalopride 01.06.07 Non Formulary Constipation (women) - prucalopride (TA211)
Ranibizumab 11.08.02 Non Formulary Macular oedema (diabetic) - ranibizumab (TA274)
Ranibizumab 11.08.02 Non Formulary Macular oedema (retinal vein occlusion) - ranibizumab (TA283)
Ranibizumab 11.08.02 Non Formulary Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)
Retigabine 04.08.01 Non Formulary Epilepsy (partial) - retigabine (adjuvant) (TA232)
Ribavirin 05.03.05 Non Formulary Hepatitis C - peginterferon alfa and ribavirin (TA106)
Ribavirin 05.03.05 Non Formulary Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75)
Ribavirin 05.03.05 Non Formulary Hepatitis C - peginterferon alfa and ribavirin (TA200)
Riluzole 04.09.03 Non Formulary Motor neurone disease - riluzole (TA20)
Rituximab 08.02.03 Non Formulary Non-Hodgkin’s lymphoma - rituximab (TA65)
Rituximab 08.02.03 Non Formulary Lymphoma (follicular non-Hodgkin’s) - rituximab (TA137)
Rituximab 08.02.03 Non Formulary Leukaemia (chronic lymphocytic, first line) - rituximab (TA174)
Rituximab 08.02.03 Non Formulary Lymphoma (follicular non-Hodgkin’s) - rituximab (TA226)
Rituximab 08.02.03 Non Formulary Follicular lymphoma - rituximab (review) (TA243)
Rituximab 08.02.03 Non Formulary Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)
Rituximab (rheumatology) 10.01.03 Formulary Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)
Rituximab (rheumatology) 10.01.03 Formulary Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)
Rivaroxaban 02.08.02 Non Formulary Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban (TA261)
Rivaroxaban 02.08.02 Non Formulary Venous thromboembolism - rivaroxaban (TA170)
Rivaroxaban 02.08.02 Non Formulary Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)
Rivaroxaban 02.08.02 Non Formulary Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)
Roflumilast 03.03.03 Non Formulary Chronic obstructive pulmonary disease - roflumilast (TA244)
Romiplostim 09.01.04 Non Formulary Thrombocytopenic purpura - romiplostim (TA221)
Ruxolitinib 08.01.05 Non Formulary Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (TA289)
Somatropin 06.05.01 Non Formulary Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)
Somatropin 06.05.01 Non Formulary Growth hormone deficiency (adults) - human growth hormone (TA64)
Sorafenib 08.01.05 Non Formulary Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) (TA189)
Sunitinib 08.01.05 Non Formulary Renal cell carcinoma - sunitinib (TA169)
Sunitinib 08.01.05 Non Formulary Gastrointestinal stromal tumours - sunitinib (TA179)
Sunitinib 08.01.05 Non Formulary Renal cell carcinoma (TA178)
Tacrolimus 13.05.03 Non Formulary Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)
Tadalafil 07.04.05 Non Formulary Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Tegafur with Uracil 08.01.03 Non Formulary Colorectal cancer - capecitabine and tegafur uracil (TA61)
Telaprevir 05.03.03 Non Formulary Hepatitis C (genotype 1) - telaprevir (TA252)
Telbivudine 05.03.03.01 Non Formulary Osteosarcoma - mifamurtide (TA235)
Telbivudine 05.03.03.01 Non Formulary Hepatitis B - telbivudine (TA154)
Temozolomide 08.01.05 Non Formulary Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121)
Temozolomide 08.01.05 Non Formulary Brain cancer - temozolomide (TA23)
Temsirolimus 08.01.05 Non Formulary Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) (TA207)
Temsirolimus 08.01.05 Non Formulary Renal cell carcinoma (TA178)
Tenofovir Disproxil 05.03.01 Non Formulary Hepatitis B - tenofovir disoproxil fumarate (TA173)
Tenofovir Disproxil 05.03.01 Non Formulary Hepatitis B (chronic) (CG165)
Teriflunomide 08.02.04 Non Formulary Multiple sclerosis (relapsing) - teriflunomide (TA303)
Ticagrelor 02.09 Non Formulary Acute coronary syndromes - ticagrelor (TA236)
Tobramycin inhaler 05.01.04 Non Formulary Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Tocilizumab 10.01.03 Formulary Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)
Tocilizumab 10.01.03 Formulary Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)
Topotecan 08.01.05 Non Formulary Cervical cancer (recurrent) - topotecan (TA183)
Topotecan 08.01.05 Non Formulary Lung cancer (small-cell) - topotecan (TA184)
Topotecan 08.01.05 Non Formulary Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) (TA91)
Topotecan 08.01.05 Non Formulary Cervical cancer - cervical screening (review) (TA69)
Trabectedin 08.01.05 Non Formulary Soft tissue sarcoma - trabectedin (TA185)
Trabectedin 08.01.05 Non Formulary Ovarian cancer (relapsed) - trabectedin (TA222)
Trastuzumab 08.01.05 Non Formulary Breast cancer (early) - trastuzumab (TA107)
Trastuzumab 08.01.05 Non Formulary Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)
Trastuzumab 08.01.05 Non Formulary Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) (TA257)
Trastuzumab 08.01.05 Non Formulary Breast cancer - trastuzumab (TA34)
Ustekinumab 13.05.03 Non Formulary Psoriasis - ustekinumab (TA180)
Ustekinumab 13.05.03 Non Formulary Psoriatic arthritis (active) - ustekinumab (TA313)
Varenicline 04.10.02 Non Formulary Smoking cessation - varenicline (TA123)
Vemurafenib 08.01.05 Non Formulary Colorectal cancer (first line) - cetuximab (TA176)
Vemurafenib 08.01.05 Non Formulary Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)
Verteporfin 11.08.02 Non Formulary Macular degeneration (age-related) - photodynamic therapy (TA68)
Verteporfin 11.08.02 Non Formulary Macular degeneration (age-related) - ranibizumab and pegaptanib (TA155)
Vinflunine 08.01.04 Non Formulary Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)
Zanamivir inhalation 05.03.04 Non Formulary Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158)
Zanamivir Injection 05.03.04 Non Formulary Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158)
Zolpidem 04.01.01 Non Formulary Insomnia - newer hypnotic drugs (TA77)
Zopiclone 04.01.01 Non Formulary Insomnia - newer hypnotic drugs (TA77)
Midlands Partnership